Philip Alan Barach Sells Shares of CELU
Philip Alan Barach sold 1,204,819 shares of CELU on June 19, 2026.
Key Points
- Philip Alan Barach sold 1,204,819 shares of CELU on June 19, 2026, with no planned trading strategy.
- Shares of CELU traded near $0.76 on Tuesday, lacking a meaningful P/E ratio due to unprofitability.
- Vanguard Capital Management LLC opened a new position in CELU, acquiring 621,105 shares worth about $826,070.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Philip Alan Barach sold 1,204,819 shares of CELU on June 19, 2026. The sale wasn't part of a prearranged trading plan, and details on the transaction's value weren't disclosed.
Other Institutional Activity in CELU
C V Starr & Co Inc held steady with their CELU holdings, maintaining 764,069 shares valued at approximately $1,016,212. Vanguard Capital Management LLC made a significant move by opening a new position, acquiring 621,105 shares worth about $826,070. Geode Capital Management, LLC increased its stake by 30,886 shares, leading to a 19.3% increase, totaling 191,076 shares valued at $254,171. BlackRock, Inc. also added to its holdings, boosting its position by 12,646 shares, a rise of 11%, bringing its total to 127,501 shares valued at $169,575. Meanwhile, Vanguard Fiduciary Trust Co entered the scene with a new stake, buying 79,874 shares worth $106,232.
Celularity Inc. Stock Down 55.7%
Shares of CELU traded near $0.76 on Tuesday. The company lacks a meaningful P/E ratio as it isn't currently profitable. CELU has a 52-week low of $0.50 and a high of $1.20. The stock's 50-day moving average is $0.85, and its 200-day moving average is $0.90.
$CELU stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Celularity Inc.
On June 19, 2026, the Philip Daniele Barach Family Trust sold 1,204,819 shares of CELU. Philip Alan Barach also sold 839,160 shares, and Daniele Wolf Barach sold the same amount on the same day. These transactions were not part of any planned trading strategies.
Analysts Set New Price Targets
On September 9, 2025, WBB Securities upgraded CELU to a "buy" rating with a price target of $6.00. Earlier, on August 18, 2025, they initiated coverage with the same rating and target. H.C. Wainwright maintained its "buy" rating with a $2.50 target on May 25, 2023, and previously maintained a $15.00 target on January 11, 2023. Morgan Stanley had downgraded the stock to "sell" with a $1.00 target on January 30, 2023.
Bottom Line
Philip Alan Barach's recent sale of CELU shares is part of a broader insider activity pattern. Investors often watch such insider moves closely for potential signals about company prospects. It's important to remember that these transactions are reported after the fact and may not reflect the current position. CELU's stock performance and analyst ratings indicate a mix of confidence and caution in the market.
Get Celularity Inc. alerts
New 13F filings, insider trades, and analyst moves on $CELU, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.